Thessaloniki

• A Phase 2b Open-label Study of Selinexor (KPT-330) in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Ended recruitment
  2024-512115-50-00 4 2016-06-22 Relapsed/Refractory DLBCL
• CheckMate 274 Ended recruitment
  2022-500630-29-00 5 2016-05-06 Subjects with High Risk Invasive Urothelial Carcinoma
• Long-Term Follow-up of Subjects With Transfusion-Dependant β-Thalassemia Treated With Ex Vivo Gene Therapy Using Autologous Hematopoietic St … Ended recruitment
  2024-513905-29-00 5 2008-10-16 Beta-thalassaemia
• Phase 1b Study of Tarlatamab in Combination with YL201 with or without Anti-PD-L1 in Subjects with Extensive Stage Small Cell Lung Cancer (D … Halted
  2024-515903-21-00 3 2025-10-31 Extensive Stage Small Cell Lung Cancer (ES-SCLC)
• A 96-Week, Prospective, Multicenter, Randomised, Double-Blind, Placebo-Controlled, Phase 3 Study to Compare Efficacy and Safety of Masitinib … Halted
  2024-516672-16-00 5 2024-02-02 Multiple Sclerosis
• A study to compare the effect of AVT16 and Entyvio® in subjects with moderate to severe active ulcerative colitis. Ended
  2023-507705-34-00 5 2025-08-29 Moderate to Severe Active Ulcerative Colitis
• Integrated PK/efficacy, safety, and immunogenicity study to demonstrate similarity of JPB898, a proposed biosimilar to nivolumab, to Opdivo® … Ended
  2023-507865-24-00 5 2025-03-28 Advanced (unresectable/metastatic) melanoma
• A Randomized, Double-blind, Multicenter, Placebo-controlled Study of Adjunctive Aticaprant Plus an Antidepressant for Relapse Prevention in … Ended
  2024-511057-22-00 5 2024-12-04 Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia
• A Phase 2 Study to Investigate Efficacy and Safety of HZN-1116 in Participants With Sjögren’s Syndrome Ended
  2023-507680-19-00 4 2024-11-28 Sjögren’s Syndrome
• rIFN-Gamma 1b in Candidemia Ended
  2024-510816-55-00 4 2024-11-08 Candidemia
• Long-Term Extension Study (AtDvance) to Evaluate the Safety and Efficacy of GSK1070806 in Participants with Moderate to Severe Atopic Dermat … Ended
  2023-508474-29-00 4 2024-10-30 Dermatitis, Atopic
• A study of efgartigimod PH20 SC given by prefilled syringe in adults with thyroid eye disease Ended
  2023-509197-35-00 5 2024-10-17 Thyroid Eye Disease (TED)
• A study to learn about how well a new drug called BAY3283142 works and how safe it is in reducing albumin in the urine of people with chroni … Ended
  2023-505755-40-00 4 2024-08-16 Chronic kidney disease
• Effects of NNC0194-0499, cagrilintide, and semaglutide alone or in combinations on liver damage and alcohol use in people with alcohol-relat … Ended
  2023-508170-28-00 4 2024-08-07 alcohol-related liver disease
• A research study comparing how well different doses of the medicine NNC0487-0111 lower blood sugar in people with type 2 diabetes Ended
  2023-509412-28-00 4 2024-07-26 Type 2 Diabetes
• A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of PLN-74809 (bexotegrast) for the tr … Ended
  2023-506185-31-00 10 2024-07-18 Idiopathic pulmonary fibrosis (IPF)
• A Study for Comparing a Generic Combination of Brinzolamide and Timolol Eye Drops versus Azarga® Eye Drops in the Treatment of Patients with … Ended
  2023-506494-35-00 5 2024-07-15 Ocular Hypertension
• A Phase 4 Multicenter, Randomized, Open-label, Efficacy Assessor-blinded Study of Risankizumab Compared to Deucravacitinib for the Treatment … Ended
  2023-509738-20-00 6 2024-07-11 Plaque Psoriasis
• A study to assess and compare safety and tolerability of 3 months treatment with salbutamol administered via MDI containing propellant HFA-1 … Ended
  2023-509001-76-00 5 2024-07-01 Asthma
• A study to test long-term treatment with spesolimab in people with a skin condition disease called hidradenitis suppurativa (HS) who took pa … Ended
  2023-508377-82-00 10 2024-06-27 Hidradenitis Suppurativa (HS)
• A study to compare effectiveness and safety of a combination of vudalimab or pembrolizumab with chemotherapy in participants with advanced l … Ended
  2023-509644-10-00 9 2024-06-27 Advanced Non-small Cell Lung Cancer
• A Study designed to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo plus atezolizumab administered i … Ended
  2023-506696-10-00 5 2024-06-18 Non-Small Cell Lung Cancer
• A Proof-of-Concept study to assess the efficacy, safety and tolerability of itepekimab (anti-IL-33 mAb) in participants with non-cystic fibr … Ended
  2023-508663-70-00 4 2024-06-18 Bronchiectasis
• Non-inferiority study between two formulations Brimonidine 0.2%/Timolol 0.5% eye drops solution Ended
  2023-507285-24-00 5 2024-05-31 Open angle glaucoma is characterized by increased intraocular pressure

Showing 505–528 of 652 trials